The U.S. Food and Drug Administration approved atezolizumab (Tecentriq; Genentech) in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. Read full press release.